What’s the big deal about orphan drugs? Well, they form the fastest-growing segment of the pharma market and dominate FDA approvals for a start. The diseases they treat might be rare, but there is nothing niche about the commitment to their development – and the potential revenues as a result.
For a quick spin round the highlights of this market and what it’ll look like by 2028, take a look at our new infographic.
Want to access the full report?
Share
Understand the context. Data-driven news and analysis for the pharma, biotech and medtech sectors.
Kelly Chamberlain may not have been at the company very long, but that didn’t stop me swooping in to find out a little more about her. Kelly has joined Norstella, ...
If you missed our recent webinar, AI and ML in Pharma: Redefining the Forecasting Landscape, then I hope it’s because you were on a lovely vacation somewhere. Now that you’re ...
There is no shortage of discussion about the opportunities presented by artificial intelligence and AI in the pharma industry. 50% of global healthcare companies plan to implement AI strategies by ...
Evaluate’s annual World Preview report is a must-read for many in the pharma industry. Each year, we pull together some of our key pharma forecasts to build a picture of ...
Can Forecasting Help Identify Market Opportunities for Pharmaceutical Companies? Forecasting serves to help pharmaceutical companies identify market opportunities, particularly when taking a sales-based approach and considering the wider competitive set. ...
Many pharmaceutical companies are harnessing digital solutions to elevate global forecasting. Digital tools, such as cloud-based, SaaS environments, are powering efficient, streamlined, and intelligent forecasting processes. But, for technological solutions ...
